Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flibanserin Risk Management Challenges: Can A REMS Prevent Alcohol Interactions?

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA seeks advisory committee views on risk of hypotension and syncope with Sprout’s sexual dysfunction drug flibanserin when used alone or in combination with alcohol, and whether these risks outweigh ‘numerically small’ benefits over placebo.

Advertisement

Related Content

Women’s Intuition: What Approval Of Sprout’s Addyi Means For Sponsors
Now Sprout Has To Sell Female Sexual Desire Drug Addyi
In Recommending Flibanserin Approval, FDA Panelists Urge Alcohol Contraindication
Sprout's Flibanserin Gets Reluctant Nod From FDA Panel, But REMS Needed
FDA Official Calls Gender Bias Claims ‘Misleading And Inaccurate’
Sprout’s Female Desire Drug: Size Of Safety Studies Doesn’t Matter To FDA
Flibanserin Fails To Improve Sexual Desire, FDA Advisory Committee Says

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel